209667-59-4

Basic information

• Product Name: 1-Boc-4-ethoxycarbonylmethylpiperazine
• Synonyms: 1-BOC-4-ETHOXYCARBONYLMETHYL PIPERAZINE;4-Ethoxycarbonylmethylpiperazine-1-carboxylic acid tert-butyl ester;tert-butyl 4-(2-ethoxy-2-oxoethyl)piperazine-1-carboxylate;tert-Butyl 4-[(ethoxycarbonyl)methyl]-piperazine-1-carboxylate
• CAS NO: 209667-59-4
• Molecular Formula: C₁₃H₂₄N₂O₄
• Molecular Weight: 272.34
• Mol File: 209667-59-4.mol
• Article Data: 20

Chemical Properties

• Boiling Point: 346.092°C at 760 mmHg
• Flash Point: 163.111°C
• Appearance: /
• Density: 1.09g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.478
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-Boc-4-ethoxycarbonylmethylpiperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Boc-4-ethoxycarbonylmethylpiperazine(209667-59-4)
• EPA Substance Registry System: 1-Boc-4-ethoxycarbonylmethylpiperazine(209667-59-4)

Safety Data

• Hazardous Substances Data: 209667-59-4(Hazardous Substances Data)

Usage

General Description

1-Boc-4-ethoxycarbonylmethylpiperazine, also known as Boc-EMPIP, is a chemical compound with the molecular formula C12H23N3O3. It is a derivative of piperazine and has a tert-butoxycarbonyl (Boc) protecting group attached to the nitrogen atom. 1-Boc-4-ethoxycarbonylmethylpiperazine is commonly used as an intermediate in the synthesis of pharmaceuticals and agrochemicals. It has also been studied for its potential use as a building block in the development of new organic compounds. Boc-EMPIP is known for its ability to react with various functional groups, making it a versatile reagent in organic chemistry. It is important to handle this compound with care and according to proper safety protocols, as it may pose health and environmental risks if not used properly.

InChI:InChI=1/C13H24N2O4/c1-5-18-11(16)10-14-6-8-15(9-7-14)12(17)19-13(2,3)4/h5-10H2,1-4H3

Upstream product

• 105-39-5 chloroacetic acid ethyl ester 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 
• 623-73-4 diazoacetic acid ethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 40004-08-8 1-(Ethoxycarbonylmethyl)piperazine 
• 105-36-2 ethyl bromoacetate 
• 623-48-3 ethyl iodoacetae 

Downstream Products

• 156478-71-6 4-[(1,1-Dimethylethoxy)carbonyl]-1-piperazineacetic acid 
• 945953-41-3 4-(2-oxoethyl)piperazine-1-carboxylic acid tert-butyl ester 
• 77279-24-4 tert-butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate 
• 1305197-28-7 N-hydroxy-2-(4-phenylacetyl-piperazin-1-yl)-acetamide 
• 1305197-27-6 2-(4-benzenesulfonyl-piperazin-1-yl)-N-hydroxy-acetamide 
• 1305197-77-6 C₁₆H₂₂N₂O₃ 
• 864442-44-4 ethyl 2-(4-benzoylpiperazin-1-yl)acetate 
• 1305197-26-5 2-(4-benzenesulfonyl-piperazin-1-yl)-N-hydroxy-acetamide 
• 890281-18-2 C₁₄H₂₀N₂O₄S 
• 549506-81-2 (4-phenylmethanesulfonyl-piperazin-1-yl)-acetic acid 
• 40004-08-8 1-(Ethoxycarbonylmethyl)piperazine 
• 1338673-52-1 tert-butyl 4-(2-hydrazinyl-2-oxoethyl)piperazine-1-carboxylate 

Relevant articles and documents

Ruthenium(III) chloride-catalyzed efficient protocol for ethyl diazoacetate insertion into the N-H bond of secondary amines

Ruthenium(III) chloride (1 mol%) alone can catalyze the insertion of ethyl diazoacetate into N-H bonds of various structurally and electronically diverse secondary cyclic amines under solvent-free conditions to afford the corresponding glycine esters in g

Compounds and Their Use in Treating Cancer

The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts and prodrugs thereof, where R1, R4, R5, R6, R7, Linker, X, Y, A, G, D and E have any of the meanings defined herein. This specification also relates to the use of such compounds and pharmaceutically acceptable salts and prodrugs thereof in methods of treatment of the human or animal body, for example in prevention or treatment of cancer. This specification also relates to processes and intermediate compounds involved in the preparation of such compounds and to pharmaceutical compositions containing them.

VINYL COMPOUNDS AS FGFR AND VEGFR INHIBITORS

FGFR and VEGFR inhibitors are provided, and compounds represented by formula (1) or formula (II) as FGFR and VEGFR inhibitors, pharmaceutically acceptable salts or tautomers thereof are specifically disclosed.